Author  
Place of duty  
Title   항암제 투여에 의한 혈소판 감소증의 예측 지표에 관한 고찰 ( Risk Factors in Anticancer Chemotherapy Induced Thrombocytopenia Requiring Platelet Transfusion )
Publicationinfo   2000 Jan; 032(06): 1093-1100.
Key_word   Anticancer chemotherapy , Thrombocytopenia , Risk factors
Full-Text  
Abstract   Purpose: Severe thrombocytopenia is a rare but life threatening side effect of anticancer chemotherapy. This study is for delineating risk factors for anticancer chemotherapy induced thrombocytopenia requiring platelet transfusion in cancer patients Materials and Methods: Ninety seven cases of cancers (stomach cancer 37, lung cancer 31 and breast cancer 29) were included in this study design. Complete blood cell counts were done at day 1 and then twice a week to find lowerest thrombocyte count in each cycle. Discriminant analysis of risk factors for chemotherapy induced thrombocytopenia requiring platelet transfusion were performed. Results: Anticancer chemotherapy induced thrombocytopenia less than 150,000/ μL developed in 18 cases (20.0%) at day 20.6±8.0 and mean platelet count was 111,06035,360/μL. Thrombocytopenia less than 100,000/μL developed in 10 cases (10.3%) at day 20.2±6.9 and mean platelet count was 56,200±30,460/μL. Among them platelet transfusions were needed in 6 cases (6.2%). Using discrininant analysis, day 1 platelet count less than 150,000/pL with total lymphocyte count less than 900/ Purpose: Severe thrombocytopenia is a rare but life threatening side effect of anticancer che- motherapy. This study is for delineating risk factors for anticancer chemotherapy induced thrombocytopenia requiring platelet transfusion in cancer patients Materials and Methods: Ninety seven cases of cancers (stomach cancer 37, lung cancer 31 and breast cancer 29) were included in this study design. Complete blood cell counts were done at day 1 and then twice a week to find lowerest thrombocyte count in each cycle. Discriminant analysis of risk factors for chemotherapy induced thrombocytopenia requiring platelet transfusion were performed. Results: Anticancer chemotherapy induced thrombocytopenia less than 150,000/ pL developed in 18 cases (20.0%) at day 20.6+8.0 and mean platelet count was 111,06035,360/pL. Tlpombocytopenia less than 100,000/pL developed in 10 cases (10.3%) at day 20.2+6.9 and mean platelet count was 56,200+30,460/pL. Among them platelet transfusions were needed in 6 cases (6.2%). Using discrininant analysis, day 1 platelet count less than 150,000/pL with total lymphocyte count less than 900/ pL were identified as risk factors for anticancer chemotherapy induced thrombocytopenia requiring platelet transfusion. Conclusion: Thrombocytopenia less than 150,000 pL with total lymphocyte count less than 900/ pL before administrating anticancer drugs are high risk factors for platelet transfusion, and needed proper managements. μL were identified as risk factors for anticancer chemotherapy induced thrombocytopenia requiring platelet transfusion. Conclusion: Thrombocytopenia less than 150,000 μL with total lymphocyte count less than 900/ μL before administrating anticancer drugs are high risk factors for platelet transfusion, and needed proper managements.
저 자   이종화(Jong Hwa Lee),한지숙(Jee Sook Hahn),박규은(Qu eh Park),고윤웅(Yun Woong Ko)